Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CHMP positive opinion on Eylea will stir up EU AMD market

This article was originally published in Scrip

Executive Summary

Experts on the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) are recommending that the European Commission gives marketing approval for Eylea (aflibercept) as a treatment of neovascular (wet) age-related macular degeneration (AMD). The recombinant anti-VEGF fusion protein has already been approved for the same indication by the FDA (scripintelligence.com, 21 November, 2011), Australia (March 2012) and Japan (scripintelligence.com, 4 September, 2012). Eylea is currently in a Phase III clinical study for wet AMD in China (scripintelligence.com, 29 November, 2011).

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC018844

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel